INVESTABOT
Equity Research
XNAS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Agios Pharmaceuticals posted Q1 2026 revenue of $20.7 million, up 137.7% from $8.7 million in Q1 2025, driven by the U.S. launch of AQVESME in thalassemia.
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 0 unique sellers · 10 accumulating - 1 trimming - 1 unchanged
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 6,455,997 | ~$239.6M | 12.2% | August 7, 2026 |
| BlackRock | 4,859,002 | ~$209.5M | — | August 13, 2024 |
| BlackRock | 5,754,957 | ~$194.7M | 9.9% | May 13, 2026 |
| Vanguard Group | 5,594,353 | ~$152.3M | — | January 29, 2026 |
| BlackRock | 5,235,429 | ~$142.5M | — | February 12, 2026 |
| State Street | 3,533,633 | ~$131.1M | 5.0% | August 7, 2026 |
| DE Shaw | 3,107,005 | ~$115.3M | 15.9% | August 14, 2026 |
| State Street | 3,364,879 | ~$113.7M | 8.3% | May 15, 2026 |
| DE Shaw | 2,681,169 | ~$90.7M | 44.0% | May 15, 2026 |
| State Street | 3,108,145 | ~$84.6M | — | February 13, 2026 |
| DE Shaw | 1,861,286 | ~$50.7M | — | February 17, 2026 |
| Citadel Advisors | 1,608,868 | ~$43.8M | — | February 17, 2026 |
| Goldman Sachs | 1,150,932 | ~$42.7M | 40.8% | August 14, 2026 |
| Morgan Stanley | 963,256 | ~$35.7M | -0.4% | August 13, 2026 |
| Citadel Advisors | 913,187 | ~$33.9M | 18.7% | August 14, 2026 |
| Morgan Stanley | 967,525 | ~$32.7M | 8.2% | May 15, 2026 |
| Goldman Sachs | 1,033,974 | ~$28.1M | — | March 25, 2026 |
| Goldman Sachs | 817,676 | ~$27.7M | -20.9% | May 15, 2026 |
| Citadel Advisors | 769,413 | ~$26.0M | -52.2% | May 15, 2026 |
| AQR Capital | 684,340 | ~$25.4M | 1779.5% | August 14, 2026 |